ARS: Broccoli Compound Sulforaphane Improves the Condition of Cell Models of Friedreich’s Ataxia

Friedreich’s ataxia is an inherited disorder caused by genetic changes that result in a deficiency of the protein frataxin. This disrupts cell function, including that of nerve cells, and gradually leads to impaired movement coordination and other severe symptoms.

The team worked with vulnerable neurons derived from three induced pluripotent stem cell lines from patients. The lines differed in the characteristics of their genetic defects. This approach makes it possible to study the disease using human cells outside the body.

The researchers compared the effects of sulforaphane with those of omaveloxolone and dimethyl fumarate. Responses varied across the cell lines: sulforaphane improved cell viability and reduced signs of oxidative stress and inflammation. In one additional cell line examined, it also increased frataxin levels.

The findings suggest that the compound may affect several processes associated with the disease at once. At the same time, differences between the cell lines highlight why potential treatments need to be tested in models with different genetic backgrounds.

The study was not a clinical trial involving patients. It does not prove that eating broccoli or taking supplements can treat Friedreich’s ataxia, and comparing drugs in cell models does not establish their clinical superiority. The next necessary step is to assess the treatment’s efficacy and safety in humans.